Jan. 27, 2026 — Siemens Healthineers and World Athletics have joined forces to inform medical teams how point-of-care testing (POCT) and diagnostic imaging can enhance athlete safety at endurance events and redefine how event medical teams support athletes and event spectators.

Jan.26, 2026 — SimonMed Imaging has unveiled an updated brand and the launch of SimonMed Longevity, a new division focused on AI-enabled preventive care and longevity screening. 

The rebrand reflects a broader strategic evolution in SimonMed’s approach to patient care, leveraging AI to expand its focus in including earlier risk identification and preventive support, alongside extensive diagnostic services. 

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, recently announced that U.S. Patent No. 12,527,885 has been granted by the United States Patent and Trademark Office (USPTO). This strengthens and extends the scope of the intellectual property portfolio for Nuclidium’s NU101 radiotheranostic program. The patent protects the Copper-61 based diagnostic as well as its use in combination with the Copper-67 based therapeutic in a theranostic setting.

Jan. 21, 2026 — Aidoc recently announced that the U.S. Food and Drug Administration (FDA) cleared the industry's first comprehensive AI triage solution^1,2, enabling health systems to surface critical findings earlier and reduce delays in patient flow amid Emergency Department (ED) crowding and imaging backlogs. This was made possible by CARE, Aidoc's self-developed AI foundation model.

Jan. 22, 2026 —  Qure.ai has received a grant from the Gates Foundation to develop a large open-source multi-modal database to further advance future prevention and identification innovations.